Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

PURPOSE: Keyhole limpet hemocyanin (KLH) attracts biomedical interest because of its remarkable immunostimulatory properties. Currently, KLH is used as vaccine adjuvant, carrier protein for haptens and as local treatment for bladder cancer. Since a quantitative human anti-KLH assay is lacking, it ha...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Aarntzen, Erik H. J. G., de Vries, I. Jolanda M., Göertz, Joop H., Beldhuis-Valkis, Marjo, Brouwers, Huberdina M. L. M., van de Rakt, Mandy W. M. M., van der Molen, Renate G., Punt, Cornelis J. A., Adema, Gosse J., Tacken, Paul J., Joosten, Irma, Jacobs, Joannes F. M.
Format: Artigo
Jezik:Inglês
Izdano: Springer-Verlag 2012
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3493659/
https://ncbi.nlm.nih.gov/pubmed/22527252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1263-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items